What question did this study set out to answer?

To investigate the clinical and biological effects of acquired oncogenic driver mutations in patients with myelodysplastic syndromes and related hematological neoplasms.

September 13, 2013Blood

Clinical and biological implications of driver mutations in myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

EPElli PapaemmanuilMemorial Sloan Kettering Cancer Center MGMoritz GerstungGerman Cancer Research Center LMLuca MalcovatiQueen's University Belfast

Discussion

Member takes

Overview

Genomic cohort study reveals how driver mutations dictate disease trajectories and survival in myelodysplastic syndromes, highlighting the role of early spliceosome alterations.

Key Points

To investigate the clinical and biological effects of acquired oncogenic driver mutations in patients with myelodysplastic syndromes and related hematological neoplasms.
Sequenced 111 genes across a cohort of 738 patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or MDS-myeloproliferative neoplasms.
Analyzed pairwise epistatic interactions among mutated genes and assessed subclonal dynamics alongside clinical outcomes including leukemia-free survival.
Oncogenic driver mutations were identified in 78% of patients, demonstrating pairwise epistatic interactions between spliceosome machinery components and epigenetic regulators.
Early driver mutations affecting RNA splicing established future disease trajectories and phenotypes under a genetic 'predestination' pattern.
Leukemia-free survival progressively deteriorated as the number of driver mutations increased, with clonal and subclonal mutations carrying equivalent adverse prognostic value.

Cite This Study

Papaemmanuil et al. (2013) studied this question.

synapsesocial.com/papers/69d8b7ecce048d2571bede79 https://doi.org/10.1182/blood-2013-08-518886

View Full Paper

Ask AI

Bookmark

September 13, 2013Blood

Clinical and biological implications of driver mutations in myelodysplastic syndromes

View Full Paper

Ask AI

Bookmark

Authors

EPElli PapaemmanuilMemorial Sloan Kettering Cancer Center MGMoritz GerstungGerman Cancer Research Center LMLuca MalcovatiQueen's University Belfast

Discussion

Member takes

Overview

Genomic cohort study reveals how driver mutations dictate disease trajectories and survival in myelodysplastic syndromes, highlighting the role of early spliceosome alterations.

Key Points

To investigate the clinical and biological effects of acquired oncogenic driver mutations in patients with myelodysplastic syndromes and related hematological neoplasms.
Sequenced 111 genes across a cohort of 738 patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or MDS-myeloproliferative neoplasms.
Analyzed pairwise epistatic interactions among mutated genes and assessed subclonal dynamics alongside clinical outcomes including leukemia-free survival.
Oncogenic driver mutations were identified in 78% of patients, demonstrating pairwise epistatic interactions between spliceosome machinery components and epigenetic regulators.
Early driver mutations affecting RNA splicing established future disease trajectories and phenotypes under a genetic 'predestination' pattern.
Leukemia-free survival progressively deteriorated as the number of driver mutations increased, with clonal and subclonal mutations carrying equivalent adverse prognostic value.

Cite This Study

Papaemmanuil et al. (2013) studied this question.

synapsesocial.com/papers/69d8b7ecce048d2571bede79 https://doi.org/10.1182/blood-2013-08-518886

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark